Öppna denna publikation i ny flik eller fönster >> Visa övriga...
2025 (Engelska) Ingår i: Toxins, E-ISSN 2072-6651, Vol. 17, nr 12, artikel-id 592Artikel i tidskrift (Refereegranskat) Published
Abstract [en] Trimethylamine-N-oxide (TMAO), a gut microbiota-derived dietary metabolite, is linked to progression of chronic kidney disease (CKD). Megalin, a renal proximal tubule receptor crucial for albumin reabsorption, also plays a role in CKD. However, the relationship between them is not well explored. The aim of this study was to investigate if there are any correlations between the levels of TMAO, megalin, lysine and markers of tubular damage in CKD. Urinary metabolites (TMAO, choline, L-carnitine, betaine, lysine) and tubular markers (megalin, albumin, EGF, MCP-1) were quantified by LC-MS/MS and ELISA. Associations were evaluated using analysis of covariance (ANCOVA) adjusted for age and diabetes, with false discovery rate correction. Compared with controls, CKD patients showed higher urinary choline (FDR < 0.001), betaine (FDR = 0.007), lysine (FDR = 0.005), and soluble megalin (FDR < 0.001) but lower EGF and EGF/MCP-1 ratio (both FDR < 0.001). Correlation analyses revealed that serum TMAO was positively associated with soluble megalin and negatively with EGF/MCP-1 ratio. Choline, L-carnitine, and betaine were positively correlated with megalin. This cross-sectional study identifies associations between urinary metabolites, megalin, and tubular injury markers in advanced CKD. Although causality cannot be inferred, the results point to a potential metabolic-tubular link that should be explored in future longitudinal and mechanistic studies.
Ort, förlag, år, upplaga, sidor
MDPI, 2025
Nyckelord TMAO, albuminuria, chronic kidney disease, lysine, megalin, tubular damage
Nationell ämneskategori
Endokrinologi och diabetes
Identifikatorer urn:nbn:se:oru:diva-125923 (URN) 10.3390/toxins17120592 (DOI) 001648218200001 () 41441627 (PubMedID) 2-s2.0-105025732111 (Scopus ID)
Forskningsfinansiär Örebro universitetKK-stiftelsenSvenska läkaresällskapet
Anmärkning Funding Agencies:
This project was financially supported by the Faculty of Medicine and Health at Örebro University, the Swedish Knowledge Foundation, European Renal Association and the Swedish Medical Association.
2025-12-292025-12-292026-01-23 Bibliografiskt granskad